Pharmaceutical News and Articles

Shorter Course of Breast Cancer Radiation Won't Affect Breast Reconstruction

could make post-mastectomy radiation a more accessible option for patients. Other research has shown that a shorter course of treatment is not only as effective

Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

FDA Approves Cobenfy (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Cobenfy (xanomeline and trospium chloride), is a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Sports Injuries: How They're Treated, and How Soon You Can Safely Return to Play

A tumble, a tackle Anything can bring on a sidelining sports injury. Now, four experts in such injuries at Penn State Health give advice on recovery and when it

DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis

CUPERTINO, Calif. , Sept. 25, 2024. DURECT Corporation, a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform t

New research confirms link between perceived stress and psoriasis relapse

AMSTERDAM, Sept. 26, 2024. Psoriasis, a chronic skin condition affecting over 6 million people in Europe, is characterized by rapid skin cell production, leadin

Blood Cancers: What You Need to Know

Blood cancer is not a diagnosis anyone wants to receive, but understanding the different types of this disease and how best to catch them early is essential, on

European Committee for Treatment and Research in Multiple Sclerosis, Sept. 18-20

For people with multiple sclerosis, a higher burden of comorbidity is associated with worse clinical outcomes, according to a study published online Sept. 18 in

More Than Half of Infants Protected by Maternal RSV Vaccine, Nirsevimab, or Both

In the 2023 to 2024 respiratory syncytial virus (RSV) season, more than half of infants were protected by maternal RSV vaccine, nirsevimab, or both, according t